262 related articles for article (PubMed ID: 9176106)
1. Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation.
Perrin PJ; Davis TA; Smoot DS; Abe R; June CH; Lee KP
Immunology; 1997 Apr; 90(4):534-42. PubMed ID: 9176106
[TBL] [Abstract][Full Text] [Related]
2. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
3. T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade.
Woodward JE; Bayer AL; Chavin KD; Blue ML; Baliga P
Transplantation; 1998 Jul; 66(1):14-20. PubMed ID: 9679816
[TBL] [Abstract][Full Text] [Related]
4. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes.
Fleischer J; Soeth E; Reiling N; Grage-Griebenow E; Flad HD; Ernst M
Immunology; 1996 Dec; 89(4):592-8. PubMed ID: 9014827
[TBL] [Abstract][Full Text] [Related]
5. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
[TBL] [Abstract][Full Text] [Related]
6. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.
Yi-qun Z; Joost van Neerven RJ; Kasran A; de Boer M; Ceuppens JL
Int Immunol; 1996 Jan; 8(1):37-44. PubMed ID: 8671587
[TBL] [Abstract][Full Text] [Related]
7. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function.
Hathcock KS; Laszlo G; Pucillo C; Linsley P; Hodes RJ
J Exp Med; 1994 Aug; 180(2):631-40. PubMed ID: 7519245
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Hoskin DW
J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
[TBL] [Abstract][Full Text] [Related]
10. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
11. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.
Barcy S; Wettendorff M; Leo O; Urbain J; Kruger M; Ceuppens JL; de Boer M
Int Immunol; 1995 Feb; 7(2):179-89. PubMed ID: 7537534
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules and dendritic cells on the immune response in leprosy.
Santos DO; Santos SL; Esquenazi D; Nery JA; Defruyt M; Lorré K; Van Heuverswyn H
Nihon Hansenbyo Gakkai Zasshi; 2001 Feb; 70(1):15-24. PubMed ID: 11244783
[TBL] [Abstract][Full Text] [Related]
13. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Freeman GJ; Borriello F; Hodes RJ; Reiser H; Gribben JG; Ng JW; Kim J; Goldberg JM; Hathcock K; Laszlo G
J Exp Med; 1993 Dec; 178(6):2185-92. PubMed ID: 7504059
[TBL] [Abstract][Full Text] [Related]
14. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients.
García-Cózar FJ; Molina IJ; Cuadrado MJ; Marubayashi M; Peña J; Santamaría M
Clin Exp Immunol; 1996 Apr; 104(1):72-9. PubMed ID: 8603537
[TBL] [Abstract][Full Text] [Related]
15. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
16. Break of neonatal Th1 tolerance and exacerbation of experimental allergic encephalomyelitis by interference with B7 costimulation.
Bell JJ; Min B; Gregg RK; Lee HH; Zaghouani H
J Immunol; 2003 Aug; 171(4):1801-8. PubMed ID: 12902480
[TBL] [Abstract][Full Text] [Related]
17. B7-mediated costimulation and the immune response.
Schultze J; Nadler LM; Gribben JG
Blood Rev; 1996 Jun; 10(2):111-27. PubMed ID: 8813343
[TBL] [Abstract][Full Text] [Related]
18. B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis.
Perrin PJ; Scott D; June CH; Racke MK
Immunol Res; 1995; 14(3):189-99. PubMed ID: 8778209
[TBL] [Abstract][Full Text] [Related]
19. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
[TBL] [Abstract][Full Text] [Related]
20. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
Schweitzer AN; Sharpe AH
J Immunol; 1998 Sep; 161(6):2762-71. PubMed ID: 9743334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
